The AI-based and Structure-based Drug Design & Optimization Core can model druggable targets (target identification) in systems setting and druggable conformational states (binding site identification); run virtual screenings against millions of real and designed compounds from various libraries to discover novel lead compounds, especially if no lead is available; optimize compounds to improve drug-likeness through fragment-based approaches and binding free energy simulations.